Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Melanoma: early-phase trial registry
89 of 269 indexed Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #36 of 28,707 conditions by registered trial count.
269 US clinical trials · 89 currently recruiting · #36 of 28,707 conditions by registered trial count
Melanoma: 269 US clinical trials tracked, 89 recruiting.
Melanoma is the subject of 269 registered US clinical trials on ClinicalTrials.gov, 89 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 184 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 20 of these trials.
Enrollment posture brief
Registry condition melanoma
OPEN 89 | RECR 33% | LATE 19 | EARLY 184 | RANK #36 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Melanoma lists 89 open slots (33% of 269 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Melanoma is recruiting below its size-band peers.
89 of 269 indexed trials (33.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Melanoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 20 of 269 trials (7.4%). 139 distinct sponsors appear on at least one study for this condition label.
-
Typical Melanoma enrolment sits around 72 participants.
Median target enrolment is 72 among the 267 trials that report a genuine target (sentinel values excluded). 155 of those (58.1%) plan for fewer than 100 participants.
-
Melanoma research is mostly interventional.
231 interventional and 38 observational studies make up this index (85.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
269 total, page 5 of 6
Minimally Invasive Groin Dissection for Melanoma
Mayo Clinic
NCT01500304
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
NCT01386580
Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma
AVAX Technologies
NCT00257465
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Memorial Sloan Kettering Cancer Center
NCT02553642
Comparison of Video-Based Versus Written Patient Education on Melanoma
University of California, Davis
NCT00826995
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
NCT00349206
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
MedImmune
NCT02027961
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Yale University
NCT02085070
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Tvardi Therapeutics, Incorporated
NCT03195699
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
GlaxoSmithKline
NCT00107718
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
Yale University
NCT02407171
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Incyte Corporation
NCT04370704
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Idera Pharmaceuticals
NCT03052205
Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients
M.D. Anderson Cancer Center
NCT00506311
Trial of pIL-12 Electroporation Malignant Melanoma
OncoSec Medical Incorporated
NCT01502293
EPO906 Therapy in Patients With Advanced Melanoma
Novartis Pharmaceuticals
NCT00035165
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
BioVex Limited
NCT00289016
A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma
St. Luke's Hospital and Health Network, Pennsylvania
NCT01986712
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Craig L Slingluff, Jr
NCT02126579
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Arcus Biosciences
NCT03629756
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
BioNumerik Pharmaceuticals
NCT00062491
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
NCT00790010
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America
NCT02482168
Health Communication in Families
Memorial Sloan Kettering Cancer Center
NCT00597961
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03652077
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
PDL BioPharma
NCT00099970
Sun Protection and Tanning Awareness in Rural Schools
University of Utah
NCT06694571
Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)
Viralytics
NCT02565992
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Nina Bhardwaj
NCT01079741
Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma
Vanderbilt-Ingram Cancer Center
NCT00466687
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Pfizer
NCT00094107
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Pfizer
NCT00043368
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
M.D. Anderson Cancer Center
NCT00833807
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
National Cancer Institute (NCI)
NCT00001577
Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma
Diwakar Davar
NCT01608594
Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma
Genzyme, a Sanofi Company
NCT00356460
Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
Emory University
NCT01526486
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
University of Texas Southwestern Medical Center
NCT02986867
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma
Alaunos Therapeutics
NCT01397708
Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis
OHSU Knight Cancer Institute
NCT01556503
A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
Cardinal Health 414
NCT02509598
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma
University of Wisconsin, Madison
NCT00590824
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
Memorial Sloan Kettering Cancer Center
NCT01682213
Dendritic Cell Activating Scaffold in Melanoma
Dana-Farber Cancer Institute
NCT01753089
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01435499
Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And Immunity
Memorial Sloan Kettering Cancer Center
NCT00580060
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Parker Institute for Cancer Immunotherapy
NCT02731729
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
National Cancer Institute (NCI)
NCT00109005
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT02032810
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
X4 Pharmaceuticals
NCT02823405
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 117 |
| Phase 2 | 67 |
| Phase 3 | 16 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Melanoma page
269 registered trials, 89 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 89 Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Melanoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Melanoma condition card totals 269 registered trials; most-linked intervention Ipilimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.